A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapyBalamayoora Theivanthiran, Brent A. Hanks|Journal of Clinical Investigation|2020Cited by 248
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Lisa H. Butterfield, Laura Rosa Brunet et al.|Journal for ImmunoTherapy of Cancer|2017Cited by 239
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of ImmunotherapyAlisha Holtzhausen, Brent A. Hanks|Cancer Immunology Research|2015Cited by 178
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapyBalamayooran Theivanthiran, Brent A. Hanks|Science Translational Medicine|2022Cited by 53
Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin SignalingNicholas C. DeVito, Brent A. Hanks|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1